Alex Philippidis

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive, worldwide license agreement that could generate more than $1.3 billion for th... See more

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last spring. Blair cited the SPDR S&P Biotech exchange-t... See more

“Stay private as long as you can continue to access capital,” venture capital investor Bruce Booth, DPhil, a partner with Atlas Venture, advised biopharma CEOs in October on his blog LifeSciVC. “One should only go public if you really can’t fund yourself ... See more

Chai Discovery has completed a $130 million Series B financing that the artificial intelligence (AI)-based de novo antibody designer says will help it accelerate its research and product development, as well as grow its commercialization efforts toward cr... See more

As Eli Lilly (NYSE: LLY) and Novo Nordisk (Nasdaq Copenhagen: NOVO-B) scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, a much smaller potential rival spotlighted positive mid-stage clinical data that captiv... See more